Side-by-side · Research reference

SelankvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED11/40 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Selank

Vesugen

Primary target

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

No GABA-receptor binding; no dependence reportedMedvedev 2007

Not applicable — does not operate via hormone axis

Origin

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Selank

Vesugen

Standard dose

150–300 mcg / dose intranasalZaderej 2014

—

Frequency

2–3× per day during stress

Not specified in available literature

Lower / starter dose

75 mcg / dose

—

Evidence basis

Human-mechanistic + Russian clinical trialsMedvedev 2007

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

10–14 day cycles, repeated as needed

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

—

Timing

Morning + early afternoon preferred

—

Half-life

Short (minutes plasma); CNS effect lasts ~3 hr

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

Selank

Vesugen

Nasal irritation

Mild burning or congestion (transient)

—

Sedation

None — distinct from benzodiazepinesMedvedev 2007

—

Dependence / withdrawal

None reported in clinical useZaderej 2014

—

Cognitive impairment

None — opposite effect (enhancement)

—

Allergic reaction

Rare hypersensitivity

—

Long-term safety

Limited Western RCT data

Unknown — no long-term RCT data

Pregnancy / OB

Avoid — insufficient data

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Vesugen

—

Relative Contraindications

Selank

·Active autoimmune disease (theoretical via immunomodulation)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Selank

Vesugen

1. Form

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Administration

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Refrigerate after reconstitution; ≤30 days. Light-protected.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Caveat

Avoid co-administration with strong sedatives or other anxiolytics initially.

—

06Stack Synergy

Selank

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)